keyword
MENU ▼
Read by QxMD icon Read
search

Hyper-CVAD

keyword
https://www.readbyqxmd.com/read/27919910/ph-like-acute-lymphoblastic-leukemia-a-high-risk-subtype-in-adults
#1
Nitin Jain, Kathryn G Roberts, Elias Jabbour, Keyur Patel, Agda Karina Eterovic, Ken Chen, Patrick Zweidler-McKay, Xinyan Lu, Gloria Fawcett, Sa A Wang, Sergej Konoplev, Richard C Harvey, I-Ming Chen, Debbie Payne-Turner, Marcus Valentine, Deborah Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Jorge Cortes, Steven Kornblau, Susan O'Brien, Sherry Pierce, Jeffrey Jorgensen, Kenna R Mills Shaw, Cheryl L Willman, Charles G Mullighan, Hagop Kantarjian, Marina Konopleva
Ph-like acute lymphoblastic leukemia (ALL) is a high-risk subtype of ALL in children. There are limited and conflicted data on the incidence and prognosis of Ph-like ALL in adults. Patients with newly-diagnosed B-ALL who received frontline chemotherapy at MD Anderson Cancer Center underwent gene expression profiling of leukemic cells to identify Ph-like ALL. Patients received hyper-CVAD (80%) or augmented-BFM (20%) regimen. Of 148 patients, 33.1% had Ph-like, 31.1% had Ph+, and 35.8% had other B-ALL subtypes (B-other)...
December 5, 2016: Blood
https://www.readbyqxmd.com/read/27843135/extended-course-and-increased-dose-of-initial-chemotherapy-for-extranodal-nasal-type-natural-killer-t-nk-t-cell-lymphoma-in-patients-60-years-old-a-single-center-retrospective-cohort-study
#2
Yan Xu, Jin Wang, Wanggang Zhang, Jie Liu, Xingmei Cao, Aili He, Yinxia Chen, Liufang Gu, Bo Lei, Pengyu Zhang, Xiaorong Ma
BACKGROUND Extranodal NK/T-cell lymphoma (ENKTL) of the nasal type is highly invasive and relatively resistant to chemotherapy. This study aimed to assess the efficacy and safety of an extended chemotherapy regimen with increased dose intensity. MATERIAL AND METHODS This was a retrospective cohort study of 69 patients <60 years old with an ECOG score 0-2 treated for ENKTL at the Second Affiliated Hospital of Xi'an Jiaotong University between January 2004 and December 2013. The outcomes were compared between patients who received >8 courses of high-intensity chemotherapy (n=37) vs...
November 11, 2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/27779442/risk-benefit-analysis-of-pediatric-inspired-versus-hyperfractionated-cyclophosphamide-vincristine-doxorubicin-and-dexamethasone-protocols-for-acute-lymphoblastic-leukemia-in-adolescents-and-young-adults
#3
Gregory F Guzauskas, Kathleen F Villa, Geertrui F Vanhove, Vicki L Fisher, David L Veenstra
PURPOSE: To estimate the risk-benefit trade-off of a pediatric-inspired regimen versus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) for first-line treatment of adolescents/young adult (AYA; ages 16-39 years) patients with Philadelphia-negative acute lymphoblastic leukemia. METHODS: Patient outcomes were simulated using a 6-state Markov model, including complete response (CR), no CR, first relapse, second CR, second relapse, and death...
October 25, 2016: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/27738441/efficacy-of-compound-kushen-injection-in-combination-with-induction-chemotherapy-for-treating-adult-patients-newly-diagnosed-with-acute-leukemia
#4
Honglei Tu, Bo Lei, Shan Meng, Hailing Liu, Yongchang Wei, Aili He, Wanggang Zhang, Fuling Zhou
We assessed the clinical effectiveness and safety of CKI (compound Kushen injection) plus standard induction chemotherapy for treating adult acute leukemia (AL). We randomly assigned 332 patients with newly diagnosed AL to control (n = 165, receiving DA (daunorubicin and cytarabine) or hyper-CVAD (fractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone)) or treatment (n = 167, receiving CKI and DA or hyper-CVAD) groups. Posttreatment, treatment group CD3+, CD4+, CD4+/CD8+, natural killer (NK) cell, and immunoglobulin (IgG, IgA, and IgM) levels were significantly higher than those of the control group (p < 0...
2016: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/27695344/primary-gastric-anaplastic-lymphoma-kinase-negative-anaplastic-large-cell-lymphoma
#5
Chen Tian, Yizhuo Zhang
INTRODUCTION: Most primary stomach lymphomas are now recognized to originate from B-cell. Primary gastric anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) as shown in this case is very rare. CASE REPORT: A 59-year-old man presented with a 1-month history of epigastric pain. Computed tomography showed a tumor in the stomach with perigastric lymphadenopathy. Biopsy of the tumor with gastroendoscopy showed ALCL. Bone marrow aspiration and trephine biopsy showed no infiltration...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27599418/mantle-cell-lymphoma-presenting-with-spontaneous-splenic-rupture
#6
Yukako Maeda-Sakagami, Yasuhiro Tanaka, Yusuke Koba, Isaku Shinzato, Takayuki Ishikawa
A 48-year-old man was transferred to our emergency room because of sudden-onset epigastric pain and nausea. Abdominal contrast-enhanced computed tomography (CT) showed splenomegaly with splenic infarction and intra-abdominal bleeding, suggestive of splenic rupture. An emergent open splenectomy was performed. His spleen was markedly swollen and showed continuous bleeding due to a laceration. On histopathological examination, his spleen was filled with abnormal tumor cells. He was diagnosed as having mantle cell lymphoma based on the findings of immunohistochemical and cytogenetic analyses of the spleen...
August 2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/27569099/8p11-myeloproliferative-syndrome-diagnostic-challenges-and-pitfalls
#7
Darko A Antic, Vojin M Vukovic, Jelena D Milosevic Feenstra, Robert Kralovics, Andrija D Bogdanovic, Marija S Dencic Fekete, Biljana S Mihaljevic
8p11 myeloproliferative syndrome (EMS) is a very rare clinicopathological entity which is characterized by the appearance of a myeloproliferative neoplasm in the bone marrow, peripheral lymphadenopathy, usually caused by T or B lymphoblastic lymphoma/leukemia, and a reciprocal translocation involving chromosome 8p11. Herein we describe a 22-year-old male patient with unusual clinical presentation of EMS. Namely, he initially presented with prolonged epistaxis. Complete blood count showed elevated hemoglobin (17...
May 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/27568673/primary-mediastinal-large-b-cell-lymphoma-and-its-mimickers-a-rare-case-report-with-literature-review
#8
T T Win, Z Kamaludin, A Husin
Primary mediastinal large B-cell lymphoma (PMLBL) is an uncommon non-Hodgkin lymphoma with a distinct clinicopathological entity in the WHO classification of lymphoid malignancies. It is known to originate from B-cells of the thymus. It mimics thymic neoplasms and other lymphomas clinically and histopathologically. We reported a 33-year-old obese man who presented with shortness of breath off and on for 4 years. Radiologically, there was a huge anterior mediastinal mass. Tru-cut biopsy was initially diagnosed as type-A thymoma...
August 2016: Malaysian Journal of Pathology
https://www.readbyqxmd.com/read/27479888/hyper-cvad-plus-ponatinib-versus-hyper-cvad-plus-dasatinib-as-frontline-therapy-for-patients-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-a-propensity-score-analysis
#9
Koji Sasaki, Elias J Jabbour, Farhad Ravandi, Nicholas J Short, Deborah A Thomas, Guillermo Garcia-Manero, Naval G Daver, Tapan M Kadia, Marina Y Konopleva, Nitin Jain, Ghayas C Issa, Vicki Jeanis, Haim G Moore, Rebecca S Garris, Naveen Pemmaraju, Jorge E Cortes, Susan M O'Brien, Hagop M Kantarjian
BACKGROUND: The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that of HCVAD plus dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial. METHODS: The authors analyzed 110 patients with newly diagnosed Ph+ ALL who were enrolled in 2 consecutive, prospective, phase 2 clinical trials of frontline HCVAD with either dasatinib (63 patients) or ponatinib (47 patients)...
August 1, 2016: Cancer
https://www.readbyqxmd.com/read/27446573/t-cell-acute-lymphoblastic-leukemia-with-co-expression-of-cd56-cd34-cd117-and-cd33-a-case-with-poor-prognosis
#10
Rafet Eren, Ceyda Aslan, Osman Yokuş, Mehmet Hilmi Doğu, Elif Suyani
T-cell acute lymphoblastic leukemia (ALL) is an aggressive hematological malignancy, accounting for ~25% of all adult cases of ALL. We herein report a case of T-cell ALL exhibiting aberrant CD34, CD56, CD33 and CD117 expression in addition to T-cell markers, which did not respond to induction treatment. A 55-year-old woman was admitted to our hospital with a sore throat unresponsive to medication for 1 month. The laboratory examination revealed pancytopenia and the peripheral blood smear examination revealed blast cells...
August 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27445489/alk-positive-anaplastic-large-cell-lymphoma-with-soft-tissue-involvement-in-a-young-woman
#11
Kehai Gao, Hongtao Li, Caihong Huang, Huazhuang Li, Jun Fang, Chen Tian
INTRODUCTION: Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma that has strong expression of CD30. ALCL can sometimes involve the bone marrow, and in advanced stages, it can produce destructive extranodal lesions. But anaplastic large cell lymphoma kinase (ALK)+ ALCL with soft tissue involvement is very rare. CASE REPORT: A 35-year-old woman presented with waist pain for over 1 month. The biopsy of soft tissue lesions showed that these cells were positive for ALK-1, CD30, TIA-1, GranzymeB, CD4, CD8, and Ki67 (90%+) and negative for CD3, CD5, CD20, CD10, cytokeratin (CK), TdT, HMB-45, epithelial membrane antigen (EMA), and pan-CK, which identified ALCL...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27409003/g80a-single-nucleotide-polymorphism-in-reduced-folate-carrier-1-gene-in-a-mexican-population-and-its-impact-on-survival-in-patients-with-acute-lymphoblastic-leukemia
#12
Myrna Candelaria, Juan Ojeda, Olga Gutiérrez-Hernández, Lucia Taja-Chayeb, Silvia Vidal-Millán, Alfonso Dueñas-González
BACKGROUND: Hyper-CVAD is the treatment for patients with acute lymphoblastic leukemia in our institution. OBJECTIVE: To evaluate the impact of single nucleotide polymorphisms at genes associated with methotrexate metabolism on survival. METHODS: The presence of the single nucleotide polymorphisms G80A at reduced folate carrier-1 gene and C677T in the methylenetetrahydrofolate reductase gene was determined by denaturing high performance liquid chromatography and validated by sequencing...
May 2016: Revista de Investigación Clínica; Organo del Hospital de Enfermedades de la Nutrición
https://www.readbyqxmd.com/read/27257042/burkitt-lymphoma-presenting-as-a-mass-in-the-thyroid-gland-a-clinicopathologic-study-of-7-cases-and-review-of-the-literature
#13
Andrés E Quesada, Huifei Liu, Roberto N Miranda, Natalia Golardi, Shahreen Billah, L Jeffrey Medeiros, Jesse Manuel Jaso
Burkitt lymphoma presenting in the thyroid gland is rare, and only a few cases have been reported. We retrospectively reviewed 7 patients diagnosed with Burkitt lymphoma of the thyroid gland between 2000 and 2015. There were 4 men and 3 women with a median age of 41 years (range, 19-49 years). All patients presented with a rapidly growing neck mass associated with upper airway compression in 5 (71%) patients. Two patients presented with localized (stage I/II) and 5 patients with disseminated (stage III/IV) disease...
October 2016: Human Pathology
https://www.readbyqxmd.com/read/27235138/impact-of-complete-molecular-response-on-survival-in-patients-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia
#14
Nicholas J Short, Elias Jabbour, Koji Sasaki, Keyur Patel, Susan M O'Brien, Jorge E Cortes, Rebecca Garris, Ghayas C Issa, Guillermo Garcia-Manero, Rajyalakshmi Luthra, Deborah Thomas, Hagop Kantarjian, Farhad Ravandi
The impact of achieving complete molecular response (CMR) in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) remains undefined. We evaluated the impact of CMR on outcomes among 85 patients with Ph(+) ALL who received first-line hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine plus a tyrosine kinase inhibitor, had minimal residual disease (MRD) assessments for BCR-ABL1 by quantitative polymerase chain reaction at complete remission (CR) and at 3-month time points, and did not undergo allogeneic stem cell transplantation (SCT)...
July 28, 2016: Blood
https://www.readbyqxmd.com/read/27203548/prognostic-impact-of-history-of-follicular-lymphoma-induction-regimen-and-stem-cell-transplant-in-patients-with-myc-bcl2-double-hit-lymphoma
#15
Shaoying Li, Annapurna Saksena, Parth Desai, Jie Xu, Zhuang Zuo, Pei Lin, Guilin Tang, C Cameron Yin, Adam Seegmiller, Jeffrey L Jorgensen, Roberto N Miranda, Nishitha M Reddy, Carlos Bueso-Ramos, L Jeffrey Medeiros
MYC/BCL2 double hit lymphoma (DHL) has been the subject of many studies; however, no study has systemically compared the clinicopathologic features and prognostic factors between patients with de novo disease versus those with a history of follicular lymphoma (FL). In addition, the prognostic importance of several other issues remains controversial in these patients. In this retrospective study, we assess 157 patients with MYC/BCL2 DHL including 108 patients with de novo disease and 49 patients with a history of FL or rarely other types of low-grade B-cell lymphoma...
June 21, 2016: Oncotarget
https://www.readbyqxmd.com/read/27178680/final-results-of-a-single-institution-experience-with-a-pediatric-based-regimen-the-augmented-berlin-frankfurt-m%C3%A3-nster-in-adolescents-and-young-adults-with-acute-lymphoblastic-leukemia-and-comparison-to-the-hyper-cvad-regimen
#16
Michael E Rytting, Elias J Jabbour, Jeffrey L Jorgensen, Farhad Ravandi, Anna R Franklin, Tapan M Kadia, Naveen Pemmaraju, Naval G Daver, Alessandra Ferrajoli, Guillermo Garcia-Manero, Marina Y Konopleva, Gautam Borthakur, Rebecca Garris, Sa Wang, Sherry Pierce, Kurt Schroeder, Steven M Kornblau, Deborah A Thomas, Jorge E Cortes, Susan M O'Brien, Hagop M Kantarjian
Several studies reported improved outcomes of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated with pediatric-based ALL regimens. This prompted the prospective investigation of a pediatric Augmented Berlin-Frankfurt-Münster (ABFM) regimen, and its comparison with hyper-fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone (hyper-CVAD) in AYA patients. One hundred and six AYA patients (median age 22 years) with Philadelphia chromosome- (Ph) negative ALL received ABFM from October 2006 through March 2014...
August 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27150061/a-childhood-chemotherapy-protocol-improves-overall-survival-among-adults-with-t-lymphoblastic-lymphoma
#17
Meng-Yuan Zhu, Hua Wang, Chun-Yu Huang, Zhong-Jun Xia, Xiao-Qin Chen, Qi-Rong Geng, Wei-da Wang, Liang Wang, Yue Lu
A broadly accepted standard treatment for adult T-lymphoblastic lymphoma (T-LBL) has not yet been defined. To address that issue, we retrospectively compared three chemotherapy regimens used to treat 110 adult patients with newly diagnosed T-LBL. These included two adult regimens (ECOG2993 and hyper-CVAD) and a childhood regimen (BFM-90). These intensive drug regimens are mainly used to treat childhood and adult acute lymphoblastic leukemia. They included induction, consolidation, and maintenance chemotherapy protocols and were administered over the course of 2 years...
June 21, 2016: Oncotarget
https://www.readbyqxmd.com/read/26870261/mantle-cell-lymphoma-with-multiple-lymphomatous-polyposis-and-intussusception-a-case-report
#18
Jae Min Lee, Eun Sun Kim, Hyuk Soon Choi, Bora Keum, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu, Insun Kim
Mantle cell lymphoma (MCL) is a rare malignant lymphoma of the gastrointestinal (GI) tract that may present as multiple lymphomatous polyposis (MLP); however, MLP with intussusception is rarely reported in MCL. In the present study, a 54-year-old male patient was diagnosed with MCL, presenting with numerous polypoid lesions of the complete GI tract combined with ileocecal intussusception. Right hemicolectomy was performed in order to prevent complicated intussusception and for tumor debulking. In addition, 6 cycles of chemotherapy were performed with the rituximab plus hyper-CVAD regimen...
January 2016: Oncology Letters
https://www.readbyqxmd.com/read/26834485/alk-positive-anaplastic-large-cell-lymphoma-with-prominent-bone-involvement-in-a-13-year-old-boy
#19
Chen Tian, Yong Yu, Hongliang Yang, Lei Zhu, Yafei Wang, Yizhuo Zhang
INTRODUCTION: Anaplastic lymphoma kinase-positive (ALK+) anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma, which has strong expression of cluster of differentiation (CD)-30 and ALK. ALCL sometimes can involve the bone marrow, and in advanced stages, it can produce destructive bone lesions. But ALK+ ALCL with prominent bone involvement is very rare, especially in children. CASE REPORT: A 13-year-old boy presented with waist pain and low-grade fever for 8 months...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/26795083/doxorubicin-based-chemotherapy-and-radiation-therapy-produces-favorable-outcomes-in-limited-stage-plasmablastic-lymphoma-a-single-institution-review
#20
Chelsea C Pinnix, Jatin J Shah, Hubert Chuang, Colleen M Costelloe, L Jeffrey Medeiros, Christine F Wogan, Valerie Reed, Grace L Smith, Sarah Milgrom, Krina Patel, Jinhai Huo, Francesco Turturro, Jorge Romaguera, Luis Fayad, Yasuhiro Oki, Michelle A Fanale, Jason Westin, Loretta Nastoupil, Fredrick B Hagemeister, Alma Rodriguez, Muzaffar Qazilbash, Nina Shah, Qaiser Bashir, Sairah Ahmed, Yago Nieto, Chitra Hosing, Eric Rohren, Bouthaina Dabaja
BACKGROUND: Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL. MATERIALS AND METHODS: We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity were assessed...
March 2016: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
27042
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"